Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
shakedown.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A community for live music fans with roots in the jam scene. Shakedown Social is run by a team of volunteers (led by @clifff and @sethadam1) and funded by donations.

Administered by:

Server stats:

270
active users

shakedown.social: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#bigpharma

2 posts2 participants0 posts today
Public *
Emeritus Prof Christopher May

Later Today POTUS Trump has vowed to sign an executive order to drastically reduce pharmaceutical prices in the USA... its not the first time he's tried this & it will be interesting to see what mechanism he proposes this time.

There will also be (and already is) massive push back from big pharma & their place-people in the Republican party.

Given big pharma was a major contributor to his campaign, this may get pretty rough... as both fight dirty!

#BigPharma #pharmaceuticals #politics

h/t FT

Public
Catherine is not giving up.

So #Today I made a choice . I’m not filling a #prescription because the price and my insurance coverage made it , while not completely unaffordable , expensive enough so that it would blow an enormous hole in a fixed income budget . We’d have no buffer for emergencies and while the spouse isn’t happy about my decision they support it .
Fuck a broken #healthcare system
Fuck #bigpharma
Fuck a country that allows a drug manufacturer to control renewing a patent .

Continued thread
Public
Miguel Afonso Caetano

"Pharmaceutical products and chemicals are the bloc’s No. 1 export to America. Among them are the weight-loss blockbuster Ozempic, cancer treatments, cardiovascular drugs and flu vaccines. Most are name-brand drugs that yield a large profit in the American market, with its high prices and vast numbers of consumers.

“These are critical things that keep people alive,” said Léa Auffret, who heads international affairs for BEUC, the European Consumer Organization. “Putting them in the middle of a trade war is highly concerning.”

European companies could react to Mr. Trump’s tariffs in a range of ways. Some pharmaceutical companies trying to dodge the tariffs have already announced plans to increase production in the United States, which Mr. Trump wants. Others could decide to move production there later.

Other companies appear to be staying put, but could raise their prices to cover the tariffs, pushing up costs for patients. And higher prices could affect not only American consumers, but also patients in Europe. Some companies have begun to argue that Europe should create more favorable conditions for their businesses by dismantling some of the rules that keep drug prices down.

Or some middle ground could play out: Companies might shift their financial profits to the United States for accounting purposes to avoid import charges, even as they leave their physical factories overseas to avoid the expenses of moving and challenges of having to set up new supply chains."

nytimes.com/2025/04/27/world/e

The New York Times · Europe’s Pharma Industry Braces for Pain as Trump Tariff Threat LoomsBy Jeanna Smialek
#USA#Trump#Tariffs
Public
Miguel Afonso Caetano

"Chief Executives don’t usually brag about paying high tax rates.
But with pharma tariffs looming, being a tax sucker is suddenly a badge of safety in the industry. That isn’t because Wall Street is suddenly in love with taxes. Rather, with so much uncertainty, investors are prizing biotech companies that base their intellectual property and manufacturing in the U.S., which up until now often meant higher taxes.

On a Thursday earnings call, Gilead Sciences Chief Executive Daniel O’Day proudly pointed out that the biotech’s corporate tax rate of approximately 20% “reflects the fact that the substantial majority of our intellectual property is already registered in the United States.”

Before the Trump era, many pharma and biotech firms established intellectual property and manufacturing operations in low-tax hubs such as Ireland. This allowed them to reduce their tax bills through transfer pricing. Essentially, the Irish unit of the company sells the drug to a U.S. unit at a high internal “transfer price,” enabling the parent company to book most of the profit in the lower-tax jurisdiction. (Ireland currently offers a headline 15% corporate tax rate to big companies, compared with 21% in the U.S.) On paper, the U.S. unit appears to earn little—even though the end-sales are largely happening in America.

While the 2017 tax overhaul under Trump was meant to curb offshore profit shifting, in practice it left key loopholes intact.

Now the second Trump administration appears to be preparing to use tariffs to target the practice, with the goal of inducing companies to increase manufacturing in the U.S. Earlier this month, the Trump administration—which has repeatedly lambasted Ireland for luring American pharma companies—announced probes into pharmaceutical imports, citing national-security concerns."

wsj.com/finance/stocks/wall-st

#USA#Trump#Tariffs
Continued thread
Public
Nonilex

Both sources, who were not authorized to speak publicly, said they expected the policy to come from the agency that oversees #Medicare and #Medicaid health programs.

The first source said he had been told directly by govt #health officials that they were exploring such a policy, which he described as a mid-level priority for the #Trump Administration as it tries to lower #drug prices.

#BigPharma#medicine
Public
Nonilex

This would be a surprisingly good thing if it happened. Somehow I doubt #BigPharma & #Republicans will allow it.

#Drugmakers have been warned that the #Trump Administration is considering linking US #medicine #prices to lower amounts paid by other developed countries, acc/to 2 company sources who called the option the pharmaceutical industry's top concern.

reuters.com/business/healthcar

Public
Emeritus Prof Christopher May

Seemingly some lower priced imports POTUS Trump does like:

In an executive order yesterday he paved the way for the importation of medicines from countries where they are cheaper, in a direct move against Big Pharma that often charges US customers around three times the lowest prices levied outside the USA.

This will surely be a popular move, but not with the Pharma sector, which (one must conclude) have done too little to seek favour at the Court of the Tangerine Tyrant.

#BigPharma#politics
Public
Joseph Lim :mastodon:

Access to #genericmeds is a #democracy issue. #BigPharma #profiteering

#Trump has Australia’s generic #medicines in his sights. And no-one’s talking about it
"There is pressure for #Australia to emulate aspects of #US system, where #drugcos can delay generics of their #meds by 30 months. If US plays hardball on tis issue cld delay 🇦🇺’s access to cheaper #generic #drugs.. US #patent notification system is much more favourable to e patented drug #companies than Australia’s"
theconversation.com/trump-has-

The ConversationTrump has Australia’s generic medicines in his sights. And no-one’s talking about itThe major parties say they won’t use the PBS as a bargaining chip in US tariff negotiations. They also need to resist pressure to slow down access to generic drugs.
Public
Mojo ♻️

For decades, American Big Pharma has been scheming to undermine Australia’s Pharmaceutical Benefits Scheme (PBS), which has given Australians access to some of the cheapest medicines in the developed world. Their goal? Higher profits at the expense of affordable healthcare. They’d love to see Australia adopt a US-style privatised system, where individuals are forced to pay exorbitant prices for the same medicines we get for just a few dollars.

#BigPharma #PBS #AffordableHealthcare #Australia #Medicare #HealthcareForAll #PharmaGreed #PublicHealth #Auspol #LNPfail

abc.net.au/news/2025-03-21/beh

ABC News · Behind America's decades-long fight to dismantle the PBSBy Ian Verrender
ExploreLive feeds
About